In this podcast episode, Dr. Andrew van Eps discusses the changes that occur in the hoof when a horse develops laminitis and describes some early clinical signs and risk factors.
In a recent study, the SGLT2 inhibitor canagliflozin showed promise as an adjunct treatment for reducing hyperinsulinemia in horses with insulin dysregulation.
Preliminary results from an ongoing study indicate that horses treated with canagliflozin have sustained decrease in postprandial insulin responses over two years without severe side effects related to...
Medical management of hyperinsulinemia with SGLT2 inhibitors is indicated for some horses, but it should be combined with appropriate management changes.
Just because it is morning doesn't mean that NSC (non-structural carbohydrates or sugars and starches) in pasture will be low. Be cautious with ID (insulin dysregulated) horses.
Equine metabolic syndrome is a collection of risk factors highly associated with an increased risk of hyperinsulinemia-associated laminitis (HAL) and potentially other morbidities, including laminitis...
